Literature DB >> 15087052

[Nosocomial infection surveillance: experience at a cardiology hospital in Mexico].

Adriana A Valenzuela-Flores1, M Sigfrido Rangel-Frausto, José N Gutiérrez-García, A Gabriela Valenzuela-Flores, Natividad Tabal-Galán.   

Abstract

OBJECTIVE: To describe the results of the Nosocomial Infection surveillance program at the Cardiology Hospital in Centro Médico Nacional Siglo XXI of the Mexican Social Security Institute.
METHODOLOGY: To inform of the epidemiologic follow-up results from January 2000 to July 2003. Global frequency, infection rates by infection site, hospital services, and frequency of most common microorganisms were estimated.
RESULTS: During this period, global incidence showed that in every 100 discharges, there were 4.3 infections (4.3/100). Frequency of infection was slightly higher in the surgical intensive care unit. Average infection rate in lower respiratory tract infections was 27/1,000; in surgical-site infections: 8/1,000 (mediastinitis 0.8/1,000); it was found that in urinary tract infection, rate was 6.6/1,000. Most commonly isolated microorganisms were: coagulase-negative Staphylococcus (25%), Enterobacter sp. (17%), Candida albicans (13%), S. aureus (9%), P. aeruginosa (9%) and K. pneumoniae (6%).
CONCLUSION: This study describes the epidemiology of nosocomial infections in a Cardiology Hospital. The information is obtained through epidemiologic follow-up programs. This information is very important to develop specific strategies for control of infections.

Entities:  

Mesh:

Year:  2004        PMID: 15087052

Source DB:  PubMed          Journal:  Cir Cir        ISSN: 0009-7411            Impact factor:   0.361


  1 in total

1.  Retrospective, Demographic, and Clinical Investigation of the Causes of Postoperative Infection in Patients With Lumbar Spinal Stenosis Who Underwent Posterior Stabilization.

Authors:  Can Yaldiz; Mahizer Yaldiz; Nehir Ceylan; Ozlem Kitiki Kacira; Davut Ceylan; Tibet Kacira; Gokhan Kizilcay; Taner Tanriverdi
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.